CYP3A4*22: Promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy

Pharmacogenomics

Volumn 14, Issue 1, 2013, Pages 47-62

  Elens, Laure ^a,b   Van Gelder, Teun ^a   Hesselink, Dennis A ^a   Haufroid, Vincent ^b,c   Van Schaik, Ron H N ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

CYP3A4; CYP3A4*22; personalized medicine; pharmacogenetics; rs35599367; single nucleotide polymorphisms; statins; tacrolimus

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ATORVASTATIN; CHLORPYRIFOS; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; CYTOSINE; ERYTHROMYCIN; EVEROLIMUS; FLUTICASONE PROPIONATE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHIONINE; MEVINOLIN; MIDAZOLAM; NIFEDIPINE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROGESTERONE; RAPAMYCIN; SIMVASTATIN; TACROLIMUS; TESTOSTERONE; THREONINE; THYMINE; UNINDEXED DRUG; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; ISOENZYME;

AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ASIAN; ASTHMA; CARDIOVASCULAR DISEASE; CAUCASIAN; DEMETHYLATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SPECIFICITY; ETHNIC DIFFERENCE; FRAMESHIFT MUTATION; GENE FREQUENCY; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GRAFT REJECTION; HUMAN; HYPERCHOLESTEROLEMIA; INDIVIDUALIZATION; INTRON; KIDNEY TRANSPLANTATION; MYOPATHY; NEGRO; NEPHROTOXICITY; NEUROLOGIC DISEASE; PATIENT CARE; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICOKINETICS; ALLELE; GENETICS; METABOLISM; METHODOLOGY; PHARMACOKINETICS;

ALLELES; CYTOCHROME P-450 CYP3A; HUMANS; INDIVIDUALIZED MEDICINE; ISOENZYMES; PHARMACOKINETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84871450636     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.187     Document Type: Review

References (91)

1. Swen JJ, Nijenhuis M, De Boer A et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89(5), 662-673 (2011).
2. Nebert DW, Adesnik M, Coon MJ et al. The P450 gene superfamily: recommended nomenclature. DNA 6(1), 1-11 (1987). (Pubitemid 17033547)
3. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 3(6), 561-597 (2002). (Pubitemid 35331660)
4. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998). (Pubitemid 28231501)
5. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001). (Pubitemid 32268418)
6. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54(10), 1271-1294 (2002). (Pubitemid 35284253)
7. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274-286 (2011).
8. Burk O, Tegude H, Koch I et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem. 277(27), 24280-24288 (2002). (Pubitemid 34951946)
9. Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin. Pharmacokinet. 45(1), 13-31 (2006). (Pubitemid 43145013)
10. Williams JA, Ring BJ, Cantrell VE et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30(8), 883-891 (2002). (Pubitemid 34815417)
11. Gorski JC, Hall SD, Jones DR, Vandenbranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47(9), 1643-1653 (1994). (Pubitemid 24167278)
12. Huang W, Lin YS, McConn DJ 2nd et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab. Dispos. 32(12), 1434-1445 (2004). (Pubitemid 39564564)
13. Kamdem LK, Streit F, Zanger UM et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem. 51(8), 1374-1381 (2005). (Pubitemid 41060869)
14. Plant N. The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim. Biophys. Acta 1770(3), 478-488 (2007). (Pubitemid 46136752)
15. Li D, Gaedigk R, Hart SN, Leeder JS, Zhong XB. The role of CYP3A4 mRNA transcript with shortened 3́-untranslated region in hepatocyte differentiation, liver development, and response to drug induction. Mol. Pharmacol. 81(1), 86-96 (2012).
16. Dong D, Wu B, Chow D, Hu M. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metab. Rev. 44(2), 192-208 (2012).
17. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J. Biol. Chem. 279(37), 38091-38094 (2004). (Pubitemid 39295952)
18. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37(6), 485-505 (1999). (Pubitemid 30032252)
19. Ozdemir V, Kalow W, Tang BK et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10(5), 373-388 (2000). (Pubitemid 30433571)
20. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5́-upstream regulatory region. Biochem. Biophys. Res. Commun. 259(1), 201-205 (1999). (Pubitemid 29264018)
21. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. 42(4), 299-305 (2003). (Pubitemid 38054375)
22. Ball SE, Scatina J, Kao J et al. Population distribution and effects on drug metabolism of a genetic variant in the 5́ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66(3), 288-294 (1999). (Pubitemid 29451761)
23. Felix CA, Walker AH, Lange BJ et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl Acad. Sci. USA 95(22), 13176-13181 (1998). (Pubitemid 28509544)
24. Garcia-Martin E, Martinez C, Pizarro RM et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther. 71(3), 196-204 (2002). (Pubitemid 34271123)
25. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90(16), 1225-1229 (1998). (Pubitemid 28407089)
26. Spurdle AB, Goodwin B, Hodgson E et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12(5), 355-366 (2002). (Pubitemid 34816415)
27. Paris PL, Kupelian PA, Hall JM et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev. 8(10), 901-905 (1999). (Pubitemid 29508726)
28. Walker AH, Jaffe JM, Gunasegaram S et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum. Mutat. 12(4), 289 (1998).
29. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5́-promoter region polymorphism. Clin. Pharmacol. Ther. 68(1), 82-91 (2000). (Pubitemid 30609830)
30. Hesselink DA, van Gelder T, van Schaik RH et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. 76(6), 545-556 (2004). (Pubitemid 39601545)
31. Hesselink DA, van Schaik RH, van der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003). (Pubitemid 37083100)
32. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 47(6), 1048-1052 (2001). (Pubitemid 32493590)
33. Wojnowski L, Hustert E, Klein K et al. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 94(8), 630-631; author reply 631-632 (2002).
34. Haufroid V, Mourad M, Van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3), 147-154 (2004). (Pubitemid 38373108)
35. Haufroid V, Wallemacq P, Vankerckhove V et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am. J. Transpl. 6(11), 2706-2713 (2006). (Pubitemid 44571691)
36. MacPhee IA. Pharmacogenetic biomarkers: cytochrome P450 3A5. Clin. Chim. Acta 413(17-18), 1312-1317 (2012).
37. Lee SJ, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 6(4), 357-371 (2005). (Pubitemid 40916359)
38. Miyazaki M, Nakamura K, Fujita Y, Guengerich FP, Horiuchi R, Yamamoto K. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone. Drug Metab. Dispos. 36(11), 2287-2291 (2008).
39. Sata F, Sapone A, Elizondo G et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67(1), 48-56 (2000). (Pubitemid 30078387)
40. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by pyrosequencing. BMC Med. Genet. 6, 19 (2005).
41. Maruf AA, Ahmed MU, Yasmin H et al. Genotypes and phenotypes of CYP3A in Bangladeshi population. Clin. Chim. Acta 412(7-8), 531-536 (2011).
42. Rais N, Chawla YK, Kohli KK. CYP3A phenotypes and genotypes in North Indians. Eur. J. Clin. Pharmacol. 62(6), 417-422 (2006). (Pubitemid 43873713)
43. Reyes-Hernandez OD, Arteaga-Illan G, Elizondo G. Detection of CYP3A4*1B and CYP3A4*2 polymorphisms by RFLP. Distribution frequencies in a Mexican population. Clin. Genet. 66(2), 166-168 (2004). (Pubitemid 39117525)
44. Cavaco I, Gil JP, Gil-Berglund E, Ribeiro V. CYP3A4 and MDR1 alleles in a Portuguese population. Clin. Chem. Lab. Med. 41(10), 1345-1350 (2003). (Pubitemid 37266126)
45. Reyes-Hernandez OD, Lares-Asseff I, Sosa-Macias M, Vega L, Albores A, Elizondo G. A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations. Pharmacology 81(2), 97-103 (2008). (Pubitemid 351182683)
46. Dai D, Tang J, Rose R et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299(3), 825-831 (2001). (Pubitemid 33104948)
47. Eiselt R, Domanski TL, Zibat A et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11(5), 447-458 (2001). (Pubitemid 32656585)
48. Hsieh KP, Lin YY, Cheng CL et al. Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos. 29(3), 268-273 (2001).
49. Wang A, Yu BN, Luo CH et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur. J. Clin. Pharmacol. 60(12), 843-848 (2005). (Pubitemid 40386153)
50. Westlind-Johnsson A, Hermann R, Huennemeyer A et al. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin. Pharmacol. Ther. 79(4), 339-349 (2006).
51. Zhou Q, Yu X, Shu C et al. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J. Hum. Genet. 56(6), 415-422 (2011).
52. Klein K, Thomas M, Winter S et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin. Pharmacol. Ther. 91(6), 1044-1052 (2012).
53. Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines. Curr. Opin. Cardiol. 21(4), 400-404 (2006). (Pubitemid 44315074)
54. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education program adult treatment panel III guidelines. Circulation 110(2), 227-239 (2004). (Pubitemid 38924592)
55. Armitage J. The safety of statins in clinical practice. Lancet 370(9601), 1781-1790 (2007). (Pubitemid 350137473)
56. Davidson MH, Maki KC, Pearson TA et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am. J. Cardiol. 96(4), 556-563 (2005). (Pubitemid 41132774)
57. Yan AT, Yan RT, Tan M et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am. J. Med. 119(8), 676-683 (2006). (Pubitemid 44128440)
58. Schmitz G, Schmitz-Madry A, Ugocsai P. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr. Opin. Lipidol. 18(2), 164-173 (2007). (Pubitemid 46412087)
59. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin. Pharmacol. Ther. 61(4), 410-415 (1997). (Pubitemid 27195943)
60. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63(3), 332-341 (1998). (Pubitemid 28182231)
61. Elens L, Becker ML, Haufroid V et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21(12), 861-866 (2011).
62. Wallemacq P, Armstrong VW, Brunet M et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther. Drug Monit. 31(2), 139-152 (2009).
63. Hesselink DA, van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 6(4), 323-337 (2005). (Pubitemid 40916357)
64. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin. Pharmacokinet. 49(3), 141-175 (2010).
65. Thervet E, Loriot MA, Barbier S et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6), 721-726 (2010).
66. Elens L, Bouamar R, Hesselink DA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57(11), 1574-1583 (2011).
67. Elens L, van Schaik RH, Panin N et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12(10), 1383-1396 (2011).
68. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br. J. Clin. Pharmacol. 72(6), 948-957 (2011).
69. Passey C, Birnbaum AK, Brundage RC et al. Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics 13(10), 1141-1147 (2012).
70. Elens L, Hesselink DA, van Schaik RH, van Gelder T. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimuspredose concentrations. Br. J. Clin. Pharmacol. doi:10.1111/bcp.12038 (2012) (Epub ahead of print).
71. Dai Y, Iwanaga K, Lin YS et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem. Pharmacol. 68(9), 1889-1902 (2004). (Pubitemid 39278511)
72. Tang HL, Ma LL, Xie HG, Zhang T, Hu YF. Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis. Pharmacogenet. Genomics 20(9), 525-531 (2010).
73. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 CT polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet. Genomics 22(5), 373-380 (2012).
74. Cummins CL, Jacobsen W, Christians U, Benet LZ. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J. Pharmacol. Exp. Ther. 308(1), 143-155 (2004). (Pubitemid 38090712)
75. Wrighton SA, Brian WR, Sari MA et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38(2), 207-213 (1990). (Pubitemid 20255306)
76. He P, Court MH, Greenblatt DJ, von Moltke LL. Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab. Dispos. 34(7), 1198-1207 (2006).
77. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10(3), 187-216 (2000). (Pubitemid 30242736)
78. Elens L, Nieuweboer AJ, Clarke SJ et al. Association between the CYP3A4*22 allele and the pharmacokinetics of the CYP3A4 phenotyping probes midazolam and erythromycin in cancer patients. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Washington, DC, USA, 15 March 2012.
79. Patki KC, Von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab. Dispos. 31(7), 938-944 (2003). (Pubitemid 36759065)
80. Roberts PJ, Rollins KD, Kashuba AD et al. The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab. Dispos. 36(8), 1465-1469 (2008).
81. Picard N, Djebli N, Sauvage FL, Marquet P. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab. Dispos. 35(3), 350-355 (2007). (Pubitemid 46333896)
82. Woillard J, Kamar N, Rostaing L, Marquet P, Picard N. Effect of a new functional CYP3A4 polymorphism on sirolimus in vitro metabolism and kidney transplant recipients trough levels. Presented at: 7ème Congrès de Physiologie, de Phamracologie et de Thérapeutique. Dijon, France, 4-6 April 2012.
83. Elens L, Mourad M, Delefortrie Q et al. Impact of CYP3A4*22 allele on sirolimus dose requirement in kidney transplant patients. Presented at: 24th International Congress of the Transplantation Society. Berlin, Germany, 15-20 July 2012.
84. Stockmann C, Ward RM, Nkoy F et al. Intronic cytochrome P450 polymorphism and pediatric asthma control with inhaled fluticasone propionate. Presented at: Pediatric Academic Societies Annual Meeting. Boston, MA, USA, 28 April-1 May 2012.
85. De Graan A-JM, Elens L, Sparreboom A et al. Influence of drug exposure and genetic variation on paclitaxel-induced neurotoxicity (1667P). Presented at: European Society for Medical Oncology (ESMO) Congress. Vienna, Austria, 28 September-2 October 2012.
86. Tayeb MT, Clark C, Ameyaw MM et al. CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 10(8), 753-756 (2000).
87. Ociepa-Zawal M, Rubis B, Filas V, Breborowicz J, Trzeciak WH. Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients. Ginekol. Pol. 80(11), 819-823 (2009).
88. Murayama N, Nakamura T, Saeki M et al. CYP3A4 gene polymorphisms influence testosterone 6b-hydroxylation. Drug Metab. Pharmacokinet. 17(2), 150-156 (2002).
89. Hu YF, Tu JH, Tan ZR et al. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 37(3), 315-327 (2007).
90. Kang YS, Park SY, Yim CH et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin. Pharmacol. Ther. 85(3), 312-318 (2009).
91. Zeng Y, He YJ, He FY, Fan L, Zhou HH. Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. Acta Pharm. Sinica 30(4), 478-484 (2009).